Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies

References

• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A. 2001;56(3):M146–M157.
   Google Scholar
• Yoon S-J, Kim K-I. Frailty and disability in diabetes. Ann Geriatr Med Res. 2019;23(4):165–169.
   PubMed Web of Science ®Google Scholar
• García-Esquinas E, Graciani A, Guallar-Castillón P, et al. Diabetes and risk of frailty and its potential mechanisms: a prospective cohort study of older adults. J Am Med Dir Assoc. 2015 2015/09/01/;16(9):748–754.
   PubMed Web of Science ®Google Scholar
• Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353–360.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence UK. Type 2 diabetes in adults: management [NG28]: National Institute for Health and Care Excellence UK; 2015 [cited 2019 Aug 15]. Available from: www.nice.org.uk/guidance/ng28/
   Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S61.
   PubMedGoogle Scholar
• RC T, RR H, CA C, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMedGoogle Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430.
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, Genuth S, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Li W, Katzmarzyk PT, Horswell R, et al. HbA1c and all-cause mortality risk among patients with type 2 diabetes. Int J Cardiol. 2016;202:490–496.
   PubMed Web of Science ®Google Scholar
• Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud. 2014 Summer;11(2):138–152.
   PubMedGoogle Scholar
• Anyanwagu U, Mamza J, Donnelly R, et al., Relationship between HbA1c and all-cause mortality in older patients with insulin-treated type 2 diabetes: results of a large UK cohort study. Age Ageing. 2019;48(2): 235–240.
   PubMedGoogle Scholar
• Anyanwagu UC, Mamza JB, Mehta R, et al. Association between hba1c with cardiovascular (CV) events and all-cause mortality in elderly patients with insulin-treated type 2 diabetes (T2D). Diabetes. 2016;65(Supplement 1):A368.
   Google Scholar
• Dunning T, Sinclair A. The IDF global guideline for managing older people with type 2 diabetes: implications for nurses. J diabetes nurs. 2014;18(4):145–150.
   Google Scholar
• Dunning T, Sinclair A, Colagiuri S. New IDF guideline for managing type 2 diabetes in older people. Diabetes Res Clin Pract. 2014;103(3):538–540.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Morley JE, Rodriguez-Mañas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the international task force of experts in diabetes. J Am Med Dir Assoc. 2012 Jul;13(6):497–502.
   PubMed Web of Science ®Google Scholar
• Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003 May;51(5 Suppl Guidelines):S265–80.
   PubMedGoogle Scholar
• Morisaki N, Watanabe S, Kobayashi J, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc. 1994 Feb;42(2):142–145.
   PubMedGoogle Scholar
• Sloan FA, Ostermann J, Brown DS, et al. Effects of changes in self-reported vision on cognitive, affective, and functional status and living arrangements among the elderly. Am J Ophthalmol. 2005;140(4):618.e1–618.e12.
   Google Scholar
• Heller SR, Pratley RE, Sinclair A, et al. Glycaemic outcomes of an individualized treatMent aPproach for oldER vulnerable patIents: a randomized, controlled stUdy in type 2 diabetes mellitus (IMPERIUM). Diabetes Obes Metab. 2018;20(1):148–156.
   PubMedGoogle Scholar
• Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444.
   PubMed Web of Science ®Google Scholar
• Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc. 2007 Dec;55(12):2041–2044.
   PubMed Web of Science ®Google Scholar
• Ogendo -J-J. Systematic review and meta-analysis of randomised control trials addressing the outcomes of intensive versus conventional HbA1c control in older, frail adults with type 2 diabetes mellitus. CRD42020175114 PROSPERO PROSPERO 2020: PROSPERO; 2020 [22/01/2021]. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020175114
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.1. 2020.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Moola SM, Tufanaru Z, Aromataris C, et al. chapter 7: systematic reviews of etiology and risk, JBI Man Evid Synth. 2020.
   Google Scholar
• Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010 Apr;1(2):97–111.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557.
   PubMed Web of Science ®Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–129.
   Web of Science ®Google Scholar
• Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens. 2005;19 Suppl 1:S27–32.
   PubMedGoogle Scholar
• Davis KL, Wei W, Meyers JL, et al. Association between different hemoglobin A1c levels and clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus. J Am Med Dir Assoc. 2014 Oct;15(10):757–762.
   PubMedGoogle Scholar
• Doucet J, Verny C, Balkau B, et al. Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: the GERODIAB observational cohort. Diabetes Metab. 2018 Dec;44(6):465–472.
   PubMedGoogle Scholar
• Hamada S, Gulliford MC. Mortality in individuals aged 80 and older with Type 2 diabetes mellitus in relation to glycosylated hemoglobin, blood pressure, and total cholesterol. J Am Geriatr Soc. 2016 Jul;64(7):1425–1431.
   PubMed Web of Science ®Google Scholar
• Huang ES, Liu JY, Moffet HH, et al. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34(6):1329–1336.
   PubMed Web of Science ®Google Scholar
• Lee R, Sloane R, Pieper C, et al. Effect of hemoglobin A1c and treatment regimen on fracture risk among older men with diabetes mellitus. J Bone Miner Res. 2018;33(Supplement 1):272.
   Google Scholar
• Ling S, Zaccardi F, Lawson C, et al. Glucose control, sulfonylureas, and insulin treatment in elderly people with Type 2 diabetes and risk of severe hypoglycemia and death: an observational study. Diabetes Care. 2021;44(4):dc200876.
   Google Scholar
• Oliver A, Chodosh J, Ferris R, et al. Over-treatment of older adults with diabetes and dementia. J Am Geriatr Soc. 2019;67(Supplement 1):S120.
   Google Scholar
• Puar THK, Ng JM, Chen RY, et al. The correlation between HbA1c and risk of femoral fractures in elderly patients. Diabetologia. 2011;54(SUPPL. 1):S518.
   Google Scholar
• Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008 Mar;31(3):391–396.
   PubMed Web of Science ®Google Scholar
• Van Hateren KJJ, Landman GWD, Kleefstra N, et al. Diabetes duration: a crucial factor when determining individual target levels of glycaemic control in old age? (ZODIAC-20). Diabetologia. 2010;53(SUPPL. 1):S166.
   Google Scholar
• Ying DG, Ko SH, Li YC, et al. Association between intensive glycemic control and mortality in elderly diabetic patients in the primary care: a retrospective cohort study. Prim Care Diabetes. 2020;14(5):476–481.
   PubMedGoogle Scholar
• Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012;35(7):1525–1531.
   PubMed Web of Science ®Google Scholar
• Tang Y, Shah H, Bueno Junior CR, et al. Intensive risk factor management and cardiovascular autonomic neuropathy in Type 2 Diabetes: the ACCORD trial. Diabetes Care. 2021;44(1):164.
   PubMedGoogle Scholar
• Chen Y, Wang J, Wang LJ, et al. Effect of different blood glucose intervention plans on elderly people with type 2 diabetes mellitus combined with dementia. Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2702–2707.
   PubMedGoogle Scholar
• Ohkuma T, Chalmers J, Cooper M, et al. The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: results from the ADVANCE trial. Diabetes Obesity Metab. 2021;23:1292–1300.
   PubMed Web of Science ®Google Scholar
• Desouza CV, Bolli GB, Fonseca VH. Diabetes, and cardiovascular events. Diabetes Care. 2010;33(6):1389.
   PubMed Web of Science ®Google Scholar
• Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications. 2012;26(5):399–406.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, McNicholas E, Sinclair AJ. Hypoglycemia, frailty and dementia in older people with diabetes: reciprocal relations and clinical implications. J Diabetes Complications. 2016;30(8):1548–1554.
   PubMedGoogle Scholar
• Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
   PubMed Web of Science ®Google Scholar
• Suh SW, Gum ET, Hamby AM, et al. Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. J Clin Invest. 2007 April/02/;117(4):910–918.
   PubMed Web of Science ®Google Scholar
• Languren G, Montiel T, Julio-Amilpas A, et al. Neuronal damage and cognitive impairment associated with hypoglycemia: an integrated view. Neurochem Int. 2013;63(4):331–343.
   PubMedGoogle Scholar
• Kirchhoff B, Lugar H, Smith S, et al. Hypoglycaemia‐induced changes in regional brain volume and memory function. Diabetic Med. 2013;30(4):e151–e156.
   PubMedGoogle Scholar
• Karagiannis T, Tsapas A, Athanasiadou E, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021 Apr;174:108737.
   PubMed Web of Science ®Google Scholar
• Røder ME. Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Ther Adv Chronic Dis. 2017;9(1):33–50.
   PubMedGoogle Scholar
• Yabe D, Shiki K, Suzaki K, et al. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021 Apr 7;11(4):e045844.
   PubMed Web of Science ®Google Scholar